Revance Therapeutics reported $7.89M in Cost of Sales for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Abbvie ABBV:US $ 4021M 259M
Aerie Pharmaceuticals AERI:US $ 6.78M 0.71M
ALKERMES ALKS:US 55.16M 1.48M
Bristol Myers Squibb BMY:US $ 2471M 115M
Coherus Biosciences CHRS:US $ 9.37M 2.73M
Eli Lilly And LLY:US $ 2072.1M 21.9M
Endo International Ordinary Shares ENDP:US $ 179.76M 42.71M
Horizon Pharma HZNP:US $ 215.06M 26.45M
JAZZ PHA JAZZ:US $ 115.28M 20.87M
Johnson & Johnson JNJ:US $ 7598M 357M
Merk MRK:US $ 5334M 1507M
Neurocrine Biosciences NBIX:US $ 4.6M 0.5M
Pacira Pharmaceuticals PCRX:US $ 36.07M 2.93M
Procter & Gamble PG:US $ 10326M 338M
Revance Therapeutics RVNC:US $ 7.89M 12K
Supernus Pharmaceuticals SUPN:US $ 17.93M 0.94M
Teva Pharmaceutical Industries TEVA:US $ 1859M 116M